Article
Clinical Neurology
Federica Garri, Francesco Paolo Russo, Tommaso Carrer, Luca Weis, Francesca Pistonesi, Michele Mainardi, Michele Sandre, Edoardo Savarino, Fabio Farinati, Francesca Del Sorbo, Paola Soliveri, Daniela Calandrella, Roberta Biundo, Miryam Carecchio, Anna Lena Zecchinelli, Gianni Pezzoli, Angelo Antonini
Summary: This study retrospectively analyzed the usage of LCIG in 79 patients with Parkinson's disease and found that it has a relatively satisfactory long-term safety profile and efficacy, with a low rate of discontinuation. Peristomal complications may be a predictor of longer duration of therapy.
JOURNAL OF NEUROLOGY
(2022)
Letter
Clinical Neurology
Vlada O. Chernova, Elisabeth M. Terveer, Joffrey van Prehn, Eduard J. Kuijper, Josbert J. Keller, Andrea E. van der Meulen-de Jong, Martijn P. Bauer, Jacobus J. van Hilten, M. Fiorella Contarino
Summary: We present a case of a patient with akinetic-rigid Parkinson's disease who was treated with Levodopa-Carbidopa Intestinal Gel therapy via a PEG-J tube for motor complications. In the context of a clinical study, we successfully and safely conducted fecal microbiota transplant through a PEG-J.
PARKINSONISM & RELATED DISORDERS
(2023)
Review
Clinical Neurology
Taiji Tsunemi, Genko Oyama, Shinji Saiki, Taku Hatano, Jiro Fukae, Yasushi Shimo, Nobutaka Hattori
Summary: LCIG treatment shows significant efficacy in reducing OFF time, increasing ON time, and improving some nonmotor symptoms and quality of life in Parkinson's disease patients. Discontinuation rates are mainly related to device issues, but the convenience of discontinuation with LCIG may be an advantage.
MOVEMENT DISORDERS
(2021)
Article
Clinical Neurology
Eric Freire-Alvarez, Egon Kurca, Lydia Lopez Manzanares, Eero Pekkonen, Cleanthe Spanaki, Paola Vanni, Yang Liu, Olga Sanchez-Solino, Luigi M. Barbato
Summary: The study showed that LCIG significantly reduced dyskinesia compared to oral optimized medical treatment, and also demonstrated significant improvements in quality of life and activities of daily living in patients with advanced Parkinson's disease.
MOVEMENT DISORDERS
(2021)
Article
Clinical Neurology
Francesca Morgante, Valentina Oppo, Margherita Fabbri, Enrica Olivola, Chiara Sorbera, Rosa De Micco, Giovanna Chiara Ielo, Fabiana Colucci, Salvatore Bonvegna, Alessio Novelli, Nicola Modugno, Mariachiara Sensi, Maurizio Zibetti, Leonardo Lopiano, Alessandro Tessitore, Manuela Pilleri, Roberto Cilia, Antonio E. Elia, Roberto Eleopra, Lucia Ricciardi, Giovanni Cossu
Summary: The study showed that LCIG infusion can be effective for late elderly Parkinson's disease patients, with no significant differences in quality of life, motor and non-motor symptoms severity, side effects, and dropout rates compared to younger patients.
JOURNAL OF NEUROLOGY
(2021)
Article
Health Care Sciences & Services
Goekce Kilincalp, Anne-Christine Sjoestroem, Barbro Eriksson, Bjoern Holmberg, Radu Constantinescu, Filip Bergquist
Summary: The use of Parkinson Kinetigraph (PKG) can predict the response of Parkinson's disease patients to intestinal levodopa/carbidopa gel infusion (LCIG). If "off" periods cannot be clearly observed in the PKG, the treatment effect may be poorer, indicating the need for noninvasive infusion evaluation before surgery.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Clinical Neurology
Dag Nyholm, Wolfgang H. Jost
Summary: As Parkinson's disease progresses, treatment needs to be adjusted to maintain symptom control. Device-aided therapy, such as levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion, can provide continuous dopaminergic stimulation for patients with advanced PD. LECIG infusion has been shown to be clinically effective, with similar motor function improvement as standard levodopa-carbidopa intestinal gel (LCIG) infusion, but at lower overall levodopa doses. Real-world data will continue to be collected to establish the long-term efficacy and safety of LECIG infusion.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2022)
Article
Clinical Neurology
Fahd Baig, Mihaela Boca, Lucy Mooney, Lucy Cheminais, Marianna Selikhova, Michal Rolinski, Konrad Szewczyk-Krolikowski, Neil Collin, Alan Whone
Summary: The study presents a case series of 32 patients undergoing PIG-J insertion for LCIG therapy in a single center. The procedure, performed under local anesthesia, involves fluoroscopy-guided gastric puncture followed by secure fixation of the gastrostomy tube and placement of the gastrojejunal extension.
PARKINSONISM & RELATED DISORDERS
(2021)
Article
Clinical Neurology
R. Balestrino, T. Martone, M. Toffoli, E. Montanaro, M. Fabbri, C. A. Artusi, A. Romagnolo, M. Zibetti, M. Rizzone, S. Goldwurm, L. Lopiano, A. H. V. Schapira
Summary: This study analyzed the genetic mutations of 56 LCIG patients and retrospectively analyzed their motor and neuropsychological outcomes. The results showed no significant differences in motor or neuropsychological outcomes between patients with and without gene mutations/variants. PD patients with GBA mutations responded well to LCIG treatment in terms of motor symptoms.
NEUROLOGICAL SCIENCES
(2023)
Article
Health Care Sciences & Services
Simona Stankova, Igor Straka, Zuzana Kosutzka, Peter Valkovic, Michal Minar
Summary: Parkinson's disease is a progressive neurodegenerative disease characterized by motor and nonmotor symptoms. Orthostatic hypotension, a disabling nonmotor feature, can be improved by continuous infusion of levodopa-carbidopa intestinal gel treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Nutrition & Dietetics
Giovanni Di Nardo, Maria Beatrice Manca, Elsa Iannicelli, Giancarlo D'Ambra, Alessandro Laviano, Matteo Guarino, Pasquale Parisi, Francesco Ernesto Pontieri, Elisa Rosati, Roberto De Giorgio
Summary: Pediatric intestinal pseudoobstruction (PIPO) is a severe gut motility disorder that can lead to obstructive symptoms and impact growth and development. Intestinal decompression is crucial in managing PIPO, and percutaneous endoscopic gastrojejunostomy (PEG-J) may provide a minimally invasive approach to improve symptoms and nutritional status in patients with chronic intestinal pseudo-obstruction.
Article
Behavioral Sciences
K. Amande M. Pauls, Jussi Toppila, Maija Koivu, Johanna Eerola-Rautio, Marianne Udd, Eero Pekkonen
Summary: The study found that 10.5% of PD patients in Finland developed new-onset polyneuropathy after starting treatment with LCIG. Additionally, patients who experienced significant weight loss greater than 1.5 were more likely to develop neuropathy, while oral B-vitamin substitution may help prevent polyneuropathy related to LCIG treatment.
BRAIN AND BEHAVIOR
(2021)
Article
Pharmacology & Pharmacy
Jozsef Attila Szasz, Viorelia Adelina Constantin, Karoly Orban-Kis, Ligia Ariana Bancu, Simona Maria Bataga, Marius Ciorba, Elod Nagy, Mircea Radu Neagoe, Istvan Mihaly, Robert Mate Szasz, Krisztina Kelemen, Mihaela Simu, Szabolcs Szatmari
Summary: Treatment of Advanced Parkinson's disease using gel form of levodopa administered directly into the upper intestine can improve the quality of life for patients, but there are still unresolved questions that require further investigation.
Article
Clinical Neurology
Sandeep Thakkar, Victor S. C. Fung, Aristide Merola, Meredith Rollins, Michael J. Soileau, Norbert Kovacs
Summary: The infusion of LCIG is a standard treatment for advanced Parkinson's disease, and extending it to 24 hours may further alleviate symptoms. However, studies on 24-hour infusion are limited by small sample sizes and study designs. Clinical experience suggests that some patients may benefit from 24-hour infusion, but dose adjustments and monitoring are necessary.
Article
Neurosciences
K. Ray Chaudhuri, Norbert Kovacs, Francesco E. Pontieri, Jason Aldred, Paul Bourgeois, Thomas L. Davis, Esther Cubo, Marieta Anca-Herschkovitsch, Robert Iansek, Mustafa S. Siddiqui, Mihaela Simu, Lars Bergmann, Mayra Ballina, Pavnit Kukreja, Omar Ladhani, Jia Jia, David G. Standaert
Summary: The DUOGLOBE study demonstrates long-term reductions in motor and non-motor symptoms in patients with aPD treated with LCIG in a real-world setting.
JOURNAL OF PARKINSONS DISEASE
(2023)
Article
Clinical Neurology
Lisette H. Koens, Marrit R. Klamer, Deborah A. Sival, Bettina Balint, Kailash P. Bhatia, Maria Fiorella Contarino, Martje E. van Egmond, Roberto Erro, Jennifer Friedman, Victor S. C. Fung, Christos Ganos, Manju A. Kurian, Anthony E. Lang, Eavan M. McGovern, Emmanuel Roze, Tom J. de Koning, Marina A. J. Tijssen
Summary: This article describes an easy-to-use clinical screening tool to help nonmovement disorder specialists recognize movement disorders in patients with inborn errors of metabolism (IEMs). Through scoring videos of 55 patients with different IEMs, informative tasks including walking, observations of the arms, and drawing a spiral were identified and incorporated into the screening tool. The study suggests that this tool can assist in selecting patients who should be referred to a movement disorder specialist for further evaluation and treatment.
MOVEMENT DISORDERS
(2023)
Letter
Clinical Neurology
Nikolai Gil D. Reyes, Daniel G. Di Luca, Vanda McNiven, Anthony E. Lang
Summary: GNB1 encephalopathy is a rare neuro-developmental syndrome caused by pathogenic variants in the GNB1 gene. It is characterized by global developmental delay and co-occurrence of movement disorders, with dystonia being the most common. Other rare phenomenologies include myoclonus, tics, chorea, ataxia, and oculomotor abnormalities. This case report presents a unique phenotype of GNB1 encephalopathy caused by a de novo mutation in exon 11, with symptoms of dystonia, myoclonus, and vertical supranuclear gaze palsy.
PARKINSONISM & RELATED DISORDERS
(2023)
Letter
Clinical Neurology
Daniel G. Di Luca, Dilinuer Wubuli, Vanda McNiven, Anthony E. Lang
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Article
Clinical Neurology
Carin Janz, Jonathan Timpka, Matthias Loehle, Alexander Bremer, Florin Gandor, Georg Ebersbach, Alexander Storch, Per Odin
Summary: The study aimed to investigate the effect of structured training on motor fluctuations in improving agreement between observer and patient assessments and daily motor state times. The results showed that structured training did not significantly improve the agreement between observers and HD ratings or the reliability of daily motor state times.
ACTA NEUROLOGICA SCANDINAVICA
(2023)
Article
Clinical Neurology
Matteo Bologna, Alberto J. Espay, Alfonso Fasano, Giulia Paparella, Mark Hallett, Alfredo Berardelli
MOVEMENT DISORDERS
(2023)
Letter
Clinical Neurology
Jinyoung Youn, Carolina Gorodetsky, Andres M. Lozano, Anthony E. Lang, Alfonso Fasano
Summary: Despite no previous reports on parkinsonism in Poland syndrome (PS) and the lack of studies on treatment response, we present a case of ipsilateral parkinsonism in PS, resembling hemiatrophy-hemiparkinsonism, with a positive response to levodopa and subthalamic deep brain stimulation.
PARKINSONISM & RELATED DISORDERS
(2023)
Article
Multidisciplinary Sciences
Sabrina Schlienger, Patricia T. Yam, Nursen Balekoglu, Hugo Ducuing, Jean-Francois Michaud, Shirin Makihara, Daniel K. Kramer, Baoyu Chen, Alfonso Fasano, Alfredo Berardelli, Fadi F. Hamdan, Guy A. Rouleau, Myriam Srour, Frederic Charron
Summary: Mirror movements (MM) disorder is characterized by involuntary movements on one side of the body that mirror intentional movements on the opposite side. In this study, we identified ARHGEF7 as a candidate MM gene and demonstrated its role in Netrin-1-mediated axon guidance. We further showed that Arhgef7/Git1 acts as a multifunctional effector complex, activating Rac1 and Cdc42 and inhibiting Arf1 downstream of Netrin-1.
Review
Clinical Neurology
Massimiliano Passaretti, Alessio Maranzano, Brent Bluett, Rajasumi Rajalingam, Alfonso Fasano
Summary: Gait analysis is a reliable tool to assess gait impairment in iNPH patients. Gait parameters improve after tap-test and CSF shunt surgery, but do not completely normalize. Tap-test's effect on gait velocity reaches its peak after 24-48 hours and returns to baseline after 90-100 hours.
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Editorial Material
Clinical Neurology
Nikolai Gil D. Reyes, Anthony E. Lang
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Letter
Clinical Neurology
Seyedeh Narges Tabatabaee, Sajjad Effat Nejad, Ali Nikkhah, Narges Hashemi, Afagh Alavi, Anthony E. E. Lang, Mohammad Rohani, Maziar Emamikhah
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Article
Clinical Neurology
Daniel G. Di Luca, Carolina Ramirez-Gomez, Jurgen Germann, Brendan Santyr, Alexandre Boutet, Luka Milosevic, Anthony E. Lang, Suneil K. Kalia, Andres M. Lozano, Alfonso Fasano
Summary: This study aimed to evaluate the safety and efficacy of deep brain stimulation on the globus pallidus pars interna and externa in MSA-P patients. The surgery did not result in major complications, but did not provide significant clinical benefit as measured by MDS-UPDRS III.
MOVEMENT DISORDERS
(2023)
Article
Neurosciences
Sotirios Grigoriou, Elena Espa, Per Odin, Jonathan Timpka, Gustaf von Grothusen, Andreas Jakobsson, M. Angela Cenci
Summary: This study aimed to compare the temporal and topographic profiles of abnormal involuntary movements (AIMs) in Parkinson's disease patients under treatment with L-DOPA and the dopamine agonist ropinirole. The results showed that the combination of L-DOPA and ropinirole resulted in lower peak severity but longer duration of AIMs. This study paves the way for the introduction of a combined L-DOPA-ropinirole challenge test in the early clinical evaluation of antidyskinetic treatments.
Review
Clinical Neurology
Iris Lin, Laura Armengou-Garcia, Sanskriti Sasikumar, Greg Kuhlman, Susan H. Fox, Anthony E. Lang, Alberto J. Espay
Summary: Speech-induced craniofacial myoclonus with stuttering-like dysarthria and speech arrests is a disabling iatrogenic complication in Parkinson's disease that resolves upon amantadine discontinuation. Four of the patients with renal insufficiency were identified as a risk factor.
MOVEMENT DISORDERS CLINICAL PRACTICE
(2023)
Article
Clinical Neurology
Alberto J. Espay, Robert A. Hauser, Rohit Dhall, Sandeep Thakkar, Leslie Cloud, Leonid Zeitlin, Ghazal Banisadr, Stanley Fisher, Hester Visser
Summary: In this open-label extension of a phase 3 study, IPX203 demonstrated a favorable safety profile and sustained efficacy similar to the double-blind study. Improvements in efficacy were maintained throughout the trial, and adverse events were mostly mild or moderate and occurred within the first 90 days of treatment.
MOVEMENT DISORDERS
(2023)
Article
Clinical Neurology
Vindhya Koneru, Alberto J. Espay, Allan J. Cole, Daniel Weintraub, Kathleen Crist, Maria B. Pascual, William G. Ondo
MOVEMENT DISORDERS
(2023)